Mydecine Innovations Group Company Description
Mydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions.
The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. Its lead product drug candidates include MYCO-005 a family of psilocin analogs.
The company also develops MYCO-006 a family of MDMA analogs and MYCO-007. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds.
The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020.
Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 2013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | David Bartch |
Contact Details
Address: 1075 West Georgia Street Vancouver, British Columbia V6E 3C9 Canada | |
| Phone | 604 687 2038 |
| Website | mydecine.com |
Stock Details
| Ticker Symbol | MYCOF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA62849F1018 |
| SIC Code | 0100 |
Key Executives
| Name | Position |
|---|---|
| William Cook | Interim Chief Executive Officer and Technical Director of Mindleap Health Inc. |
| David Joshua Bartch | Co-Founder, Chief Executive Officer, President and Chairman of the Board |
| Robert Roscow M.A. | Co-Founder and Former Chief Scientific Officer |
| Damon Michaels | Co-Founder |
| John Charles Ross CA, CPA, M.B.A. | Chief Financial Officer and Corporate Secretary |
| Dr. Rakesh Jetly FRCPC, M.D. | Chief Medical Officer |
| Morgan Kervitsky | Director of Marketing |
| Michel Rudolphie | President of the European Operations |